Loading...

Teresa Helsten

Title(s)Clinical Professor, Medicine
SchoolHealth Sciences
Address9300 Campus Point Drive #7329
La Jolla CA 92037
Phone858-249-3249
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Helsten focuses first and foremost on providing excellent care for breast cancer patients. She provides neoadjuvant, adjuvant, and metastatic treatments, including endocrine therapy, chemotherapy, and targeted therapies. She actively enrolls patients to clinical trials.

    Dr. Helsten’s research is primarily focused on clinical trials chosen to bring the most cutting edge care to her patients. She runs several clinical trials and enrolls patients to these and cooperative group and investigator initiated trials at UCSD. She is a coinvestigator of the groundbreaking I-SPY 2 study (www.ispy2.org). She is actively engaged in the design and implementation of translational research projects in breast cancer. FGFR inhibitors are of particular interest.

    Education and Training
    BS - Chemistry, Massachusetts Institute of Technology - 1990
    MD - University of California, Davis - 1998
    Resident - Harbor-UCLA Medical Center - 1998-2001
    Chief Resident - Harbor-UCLA Medical Center - 2001-2002
    Oncology Fellowship - UC San Diego Medical Center - 2002-2005

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Jul 23. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. PMID: 32701140.
      View in: PubMed   Mentions:    Fields:    
    2. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 Feb 13. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137.
      View in: PubMed   Mentions: 8     Fields:    
    3. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Mol Cancer Ther. 2019 05; 18(5):1001-1011. Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. PMID: 30926636.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 Apr 01; 38(10):1059-1069. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. PMID: 32031889.
      View in: PubMed   Mentions: 2     Fields:    
    5. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 11; 16(11):1362-1389. Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. PMID: 30442736.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    6. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. PMID: 27406346.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    7. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 07; 15(7):1682-90. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27196769.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    9. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. PMID: 26247885.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    11. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 01; 22(1):259-67. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. PMID: 26373574.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    12. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. Helsten T, Schwaederle M, Kurzrock R. PMID: 26224133.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    13. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. PMID: 26243651.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    14. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015; 14(13):2121-8. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. PMID: 25950492.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    15. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. PMID: 24942463.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011 May; 14(5):563-6. Costantini C, Ale-Ali A, Helsten T. PMID: 21388255.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Differences in regulation of Drosophila and vertebrate integrin affinity by talin. Mol Biol Cell. 2008 Aug; 19(8):3589-98. Helsten TL, Bunch TA, Kato H, Yamanouchi J, Choi SH, Jannuzi AL, Féral CC, Ginsberg MH, Brower DL, Shattil SJ. PMID: 18508915.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    18. Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity. J Biol Chem. 2006 Feb 24; 281(8):5050-7. Bunch TA, Helsten TL, Kendall TL, Shirahatti N, Mahadevan D, Shattil SJ, Brower DL. PMID: 16371365.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    Teresa's Networks
    Concepts (117)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (32)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑